Medtronic announced the Food and Drug Administration approval of its Percept RC Deep Brain Stimulation system. The Percept family is the only sensing-enabled deep brain stimulation system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia as well as epilepsy, the company said in a statement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDT:
- Comcast among forgotten value stocks with potential to grow, Barron’s says
- Medtronic receives CE Mark for Micra AV2, VR2 pacemakers
- AtriCure price target lowered to $44 from $49 at Needham
- Farapulse approval coming sooner than expected for Boston Scientific, says BTIG
- NeuroPace ‘primed for continued outperformance’ in 2024, says Lake Street
